Lifastuzumab vedotin (anti-SLC34A2) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin (anti-SLC34A2) is used in the treatment of platinum-resistant ovarian cancer. Purity ≥90% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
规格
产品名称
Lifastuzumab vedotin (anti-SLC34A2), 磷酸氢二钠抗体
别名
维汀-利法妥珠单抗|利伐珠单抗维多汀(抗 SLC34A2)
英文别名
Na(+)-dependent phosphate cotransporter 2B antibody|Na(+)/Pi cotransporter 2B antibody|NaPi-2b antibody|NaPi3b antibody|SLC34A2 antibody|Sodium-dependent phosphate transport protein 2B antibody|Sodium-phosphate transport protein 2B antibody|Sodium/phosphate cotransporter 2B antibody|Solute carrier family 34 member 2 antibody|LIFA|RG-7599
Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂
No
储存条件
-80℃储存,避免反复冻融
运输条件
特低温运输
稳定性与储存
在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
图片
Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) - Flow Cytometry Flow Cytometry analysis of SK-OV-3 cells labelling SLC34A2 (red) with Lifastuzumab vedotin (anti-SLC34A2) (Ab175578). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) - ELISA Immobilized Recombinant Human SLC34A2-NhFc protein at 2.0 μg/mL can bind Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) with the EC
₅₀
of 61.75 ng/mL.
Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) - SEC The purity of Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) is more than 95% verified by HPLC.
高级数据
关联靶点(人)
SLC34A2Tchem钠依赖性磷酸转运蛋白 2B(Sodium-dependent phosphate transport protein 2B)
(0 活性数据)